Proactive Investors - Run By Investors For Investors

Amryt Pharma signs fifth distribution deal in three months, appoints new head of Europe

The agreement, covering Lebanon, Jordan and Syria, is with Pharaon Healthcare-Droguerie Mercury S.A.L, a full service distributor in pharmaceuticals
Drugs
Lojuxta is a therapy used to treat adult patients with HoFH, a rare, life-threatening, genetic cholesterol disorder

Amryt Pharma PLC (LON:AMYT) shares gained 6% on Tuesday after news the firm signed its fifth new distribution deal in approximately three months for Lojuxta, which is used to treat a rare life-threatening disease.

The agreement, covering Lebanon, Jordan and Syria, is with Pharaon Healthcare-Droguerie Mercury S.A.L , a full service distributor in pharmaceuticals.

READ: Amryt Pharma inks fourth distribution deal in three months for key product

Lojuxta is a therapy used to treat adult patients with HoFH, a genetic cholesterol disorder.

The AIM-listed company said that there are approximately 40 patients with HoFH in the countries covered by this agreement, with Lebanon in particular having a pronounced ‘founder effect.”

Dr. Joe Wiley, Amryt's chief executive officer, said: “This new agreement should help to ensure we can respond effectively to physicians’ requests regarding their patients suffering with HoFH.”

In a separate statement, Amryt Pharma also announced the appointment of Jordi Casals as the company’s head of Europe.

Casals, who has over 20 years’ experience in the pharmaceutical and biotech industry, will be responsible for leading and further developing Amryt’s European operations, including product launches.

The company said his initial focus will be on the continuing sales growth of the firm’s commercial asset, Lojuxta.

Wiley said: “His significant commercial experience of European markets will help us to drive and further develop Amryt’s growth across this key region.”

In afternoon trading, Amryt Pharma shares were 6.2% higher at 20.25p.

 -- Adds share price --

View full AMYT profile View Profile

Amryt Pharma PLC Timeline

Related Articles

Oncoprex
October 17 2018
The biotech was founded by an investment group led by scientists and driven by a no-nonsense CEO whose stake is more than just business as usual
Vial of pills
June 25 2018
Cosmos is a modern company, but the trade routes it relies on are ancient
woman at a microscope
August 02 2018
Currently undergoing phase III clinical trials, AP101 is being developed to treat Epidermolysis Bullosa, a condition which occurs prominently in children and makes skin fragile to even the faintest touch

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use